<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="preparation" /><meta name="keywords" content="Zometa; Zoledronic acid" /><meta name="IX" content="Zometa; Zoledronic acid" /><title>Zometa®: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="106147.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="106147.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=106147.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="2073.htm">6 Endocrine system</a> &gt; <a href="4439.htm">6.6 Drugs affecting bone metabolism</a> &gt; <a href="4446.htm">6.6.2 Bisphosphonates and other drugs affecting bone metabolism</a> &gt; <a href="129617.htm">Bisphosphonates</a> &gt; <a href="106146.htm">ZOLEDRONIC ACID</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="4454.htm" title="Previous: SODIUM CLODRONATE">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="207290.htm" title="Next: Denosumab">Next page</a> ►</div></div></div></div><div id="p1"><div id="sideBar"><h2>See Also</h2><ul><li><h3>AHFS Drug Information</h3></li><li><a href="http://www.medicinescomplete.com/mc/ahfs/2010/a301052.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Zoledronic Acid</a><div class="breadcrumb"><p><strong>AHFS Drug Information</strong> &gt; Miscellaneous Therapeutic Agents 92:00 &gt; Bone Resorption Inhibitors 92:24</p></div></li></ul><ul><li><h3>Stockley's Interaction Alerts (2)</h3></li><li><a href="http://www.medicinescomplete.com/mc/alerts/2010/22535-n.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Interactions of Zoledronate</a><div class="breadcrumb"><p><strong>Stockley's Interaction Alerts</strong> &gt; Interactants: Z &gt; Interactions of Zoledronate</p></div></li><li><a href="http://www.medicinescomplete.com/mc/alerts/2010/17610-x.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Interactions of Zoledronic acid</a><div class="breadcrumb"><p><strong>Stockley's Interaction Alerts</strong> &gt; Interactants: Z &gt; Interactions of Zoledronic acid</p></div></li></ul><ul><li><h3>British National Formulary (3)</h3></li><li><a href="106146.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">ZOLEDRONIC ACID</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; 6 Endocrine system &gt; 6.6 Drugs affecting bone metabolism &gt; 6.6.2 Bisphosphonates and other drugs affecting bone metabolism &gt; Bisphosphonates</p></div></li><li><a href="129624.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Aclasta®</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; 6 Endocrine system &gt; 6.6 Drugs affecting bone metabolism &gt; 6.6.2 Bisphosphonates and other drugs affecting bone metabolism &gt; Bisphosphonates &gt; ZOLEDRONIC ACID</p></div></li><li><a href="106270.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Zoledronic acid</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; Appendix 4 Intravenous additives &gt; Use of table &gt; Table of drugs given by intravenous infusion</p></div></li></ul><ul><li><h3>Stability-Indicating HPLC Methods for Drug Analysis</h3></li><li><a href="http://www.medicinescomplete.com/mc/hplc/2008/ch0025s0035.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Zoledronic Acid</a><div class="breadcrumb"><p><strong>Stability-Indicating HPLC Methods for Drug Analysis</strong> &gt; Monographs &gt; Z</p></div></li></ul><ul><li><h3>Injectable Drugs Guide</h3></li><li><a href="http://www.medicinescomplete.com/mc/idg/2010/z02-mn0001.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Zoledronic acid</a><div class="breadcrumb"><p><strong>Injectable Drugs Guide</strong> &gt; Injectable Drugs Guide &gt; Monographs &gt; Z</p></div></li></ul><ul><li><h3>Martindale: The Complete Drug Reference</h3></li><li><a href="http://www.medicinescomplete.com/mc/martindale/2009/ms-22535-n.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Zoledronate</a><div class="breadcrumb"><p><strong>Martindale: The Complete Drug Reference</strong> &gt; Drugs and Ancillary Substances &gt; By therapeutic use &gt; Bone Modulating Drugs &gt; Drug Monographs</p></div></li></ul><ul><li><h3>The Merck Index</h3></li><li><a href="http://www.medicinescomplete.com/mc/merck/2010/10187.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Zoledronic Acid</a><div class="breadcrumb"><p><strong>The Merck Index</strong> &gt; Monographs &gt; Z &gt; ZO</p></div></li></ul><ul><li><h3>Stockley's Drug Interactions</h3></li><li><a href="http://www.medicinescomplete.com/mc/stockley/2010/int-E0E0E2E3E0R0D3103.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Interactions of Zoledronate</a><div class="breadcrumb"><p><strong>Stockley's Drug Interactions</strong> &gt; Interactants, Alphabetically &gt; Z</p></div></li></ul><script type="text/javascript" src="scripts/sidebar.js"></script></div><div id="pB"><h1 id="_106146">ZOLEDRONIC ACID</h1><div id="pC" class="jN"><div class="cAJ"><span class="cAD">Additional information</span> interactions (<a href="41001i926.htm" title="Go to appendix 1">Zoledronic Acid</a>).</div><div class="cAF"><h2>Indications</h2> <p class="cAF">see under preparations</p></div><div class="cAF"><h2>Cautions</h2> <p class="cAF">correct disturbances of calcium metabolism
(e.g. vitamin D deficiency, hypocalcaemia) before starting; monitor serum electrolytes, calcium,
phosphate and magnesium; cardiac disease
(avoid fluid overload); consider dental
check-up before initiating bisphosphonate (risk of osteonecrosis of the jaw, see <a title="BNF:target-block: Bisphosphonates NICE guidance" href="129617.htm#_204274">Bisphosphonates: Osteonecrosis
of the Jaw</a>); atypical femoral fractures, see <a title="BNF:target-block: Atypical femoral fractures" href="129617.htm#_215530">MHRA/CHM advice</a>; <b>interactions:</b> Appendix 1 (bisphosphonates)</p><div class="cAV"><h3>Renal function</h3> <p class="cAX">Renal impairment and renal failure
have been reported. Before each dose ensure patient is
hydrated and assess renal function. Continue to monitor renal function
in patients at risk, such as those with pre-existing renal impairment,
those of advanced age, those taking concomitant nephrotoxic drugs
or diuretics, or those who are dehydrated. Use with
caution with concomitant medicines that affect renal function</p></div></div><div class="cAF"><h2>Contra-indications</h2> <p class="cAF">women of child-bearing potential</p></div><div class="cAF"><h2>Hepatic impairment</h2> <p class="cAF">caution in severe hepatic impairment—limited information
available</p></div><div class="cAF"><h2>Renal impairment</h2> <p class="cAF">avoid if serum creatinine above 400 micromol/litre in
tumour-induced hypercalcaemia; in advanced malignancies involving
bone, if eGFR 50–60 mL/minute/1.73 m<sup>2</sup> reduce dose to 3.5 mg
every 3–4 weeks, if eGFR 40–50 mL/minute/1.73 m<sup>2</sup> reduce
dose to 3.3 mg every 3–4 weeks, if eGFR 30–40 mL/minute/1.73 m<sup>2</sup> reduce dose to 3 mg every 3–4 weeks, avoid if eGFR less than
30 mL/minute/1.73 m<sup>2</sup> (or if serum creatinine greater than
265 micromol/litre); if renal function deteriorates in patients with
bone metastases, withhold dose until serum creatinine returns to within
10% of baseline value; avoid in Paget’s disease, treatment of postmenopausal
osteoporosis and osteoporosis in men if eGFR less than 35 mL/minute/1.73 m<sup>2</sup>; see also Cautions above</p></div><div class="cAF"><h2>Pregnancy</h2> <p class="cAF">avoid—toxicity in <i>animal</i> studies</p></div><div class="cAF"><h2>Breast-feeding</h2> <p class="cAF">avoid—no information available</p></div><div class="cAF"><h2>Side-effects</h2> <p class="cAF"> hypophosphataemia, anaemia, influenza-like symptoms
including bone pain, myalgia, arthralgia, fever and rigors; gastro-intestinal
disturbances; atrial fibrillation; headache, dizziness, conjunctivitis,
renal impairment (rarely acute renal failure); <i>less commonly</i> anorexia, taste disturbance, dry mouth, stomatitis, chest pain,
hypertension, hypotension, dyspnoea, cough, paraesthesia, tremor,
anxiety, lethargy, sleep disturbance, blurred vision, weight gain,
pruritus, rash, sweating, muscle cramps, haematuria, proteinuria,
urinary frequency, hypersensitivity reactions (including angioedema),
asthenia, peripheral oedema, thrombocytopenia, leucopenia, hypomagnesaemia,
hypokalaemia, also injection-site reactions; <i>rarely</i> bradycardia, confusion, hyperkalaemia, hypernatraemia, pancytopenia,
osteonecrosis of the jaw (see <a title="BNF:target-block: Bisphosphonates NICE guidance" href="129617.htm#_204274">Bisphosphonates: Osteonecrosis
of the Jaw</a>),
atypical femoral fractures (see <a title="BNF:target-block: Atypical femoral fractures" href="129617.htm#_215530">MHRA/CHM advice</a>); <i>very rarely</i> uveitis and episcleritis</p></div><div class="cAF"><h2>Dose</h2> <p class="cR">See under preparations</p></div></div><?highlighter on?><div id="pS"><p>Sub-sections</p><ul class="jT"><li><a href="129624.htm#_129624" title="Aclasta®">Aclasta®</a></li><li class="jN" id="_106147" style="margin: 0 0 0 20px;"><h1 class="title">Zometa®<span> (<a href="appendix-112803-N.htm#m264">Novartis</a>)</span> <img class="cJ" src="images/pom_l.png" title="Prescription-only Medicine" alt="Prescription-only Medicine" /></h1><div class="cAY"><span class="cAB">Concentrate for intravenous infusion</span>, zoledronic acid, 800 micrograms/mL, net price 5-mL (4-mg) vial
= £174.17</div><div class="cAY"><span class="cAB">Solution for intravenous infusion</span>, zoledronic acid, 40 micrograms/mL, net price 100-mL (4-mg) bottle
= £174.14<div class="cAQ"><div class="cAF"><h2>Dose</h2> <p class="cAF">reduction of bone damage in advanced malignancies
involving bone, <span class="cU">by intravenous infusion</span>, 4 mg over
at least 15 minutes every 3–4 weeks; <span class="cAK">child</span> not recommended</p><div class="cAV"><h3>Note</h3> <p class="cAX">Calcium 500 mg daily and vitamin D 400 units
daily should also be taken</p></div><p>Hypercalcaemia of malignancy, <span class="cU">by intravenous infusion,</span> 4 mg as a single dose over at least 15 minutes; <span class="cAK">child</span> not recommended</p></div></div><div class="cAV"><h3>Note</h3> <p class="cAX">The <i><a title="BNF:target-block: NICE and Scottish Medicines Consortium" href="29404.htm#_200790">Scottish Medicines Consortium</a></i>  has advised (May 2003) that for the prevention of skeletal related
events <span class="cZ">Zometa</span>® is accepted for restricted use within
NHS Scotland for the treatment of patients with breast cancer and
multiple myeloma if prescribed by an oncologist</p></div></div></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="4454.htm">Previous: SODIUM CLODRONATE</a> | <a class="top" href="106147.htm#">Top</a> | <a accesskey="]" href="207290.htm">Next: Denosumab</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>